Clinical Trials Directory

We are doing this study to find out if an investigational drug called CA-4948 is a safe and effective option for people with PCNSL. We want to know how well it works when it is combined with a drug called ibrutinib, which is commonly used to treat PCNSL.

We are doing this study to find out if an experimental drug called CT01681 (the study drug) is a safe and effective option for people who get CAR T-cell therapy as a treatment for diffuse large B cell lymphoma (DLBCL). We want to know if the study drug has the potential to lower or prevent certain side effects of CAR T-cell therapy. The possible side effects of CAR T-cell therapy that the study drug is being developed to protect against are called cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This study is enrolling people who will receive an available form of CAR T-cell therapy called YESCARTA.

We are doing this study to see if an experimental combination of drugs (D2C7-IT and 2141-V11) is a safe treatment for brain tumors.

The purpose of this study is to find out if giving two medicines, D2C7-IT and 2141-V11, directly into the part of the brain where the tumor is left after surgery is safe and works well. After that, patients will get regular shots of 2141-V11 under the skin near the lymph nodes in the head and neck. This study is for people who have a brain cancer called recurrent glioblastoma.

To join this study, you will go to Duke hospital for surgery. During surgery, doctors will place a small tube called a catheter to give you the study medicine and take a tiny piece of tissue for research. After surgery, you will stay in the hospital while the first medicine, called D2C7-IT, goes in for about three days. Then you will get another medicine called 2141-V11, which takes about seven hours. After the medicines are done, the tube will be removed, and you will be watched for six hours. About two weeks later, you will come back to start getting shots of 2141-V11 under your skin. You may keep getting these shots for up to a year, and even longer if you want. When you stop the shots, your doctor will decide what follow-up you need.

We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.

If you join this study, you will be placed into one of two groups by chance. Most people will take a daily pill called tirabrutinib. A smaller group will receive standard treatment with a medicine called rituximab through a vein and another medicine called temozolomide taken by mouth. Treatment happens in cycles that last 28 days. Some people may keep taking the treatment as long as it is helping and safe. During the study, you will have regular doctor visits, scans such as MRI, lab tests, and check ins to watch your health.

We are doing this study to test the safety and effectiveness of the study drug, datopotamab deruxtecan (also known as dato-DXd), and find out if it is a potential option for patients with metastatic breast cancer that has spread to the brain and/or spinal cord.